SVB Leerink
Prometheus Biosciences Prices Upsized $190M IPO
The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating
The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.
First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips
The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations.
Investment Banks Initiate Coverage of Centogene With Bullish Outlooks
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
Jul 26, 2018
Veracyte Prices $51.3M Public Offering
May 14, 2015
Leerink Upgrades Invitae to Outperform
Mar 18, 2015
Leerink Upgrades T2 Bio Shares to Outperform
Apr 14, 2014
Leerink Swann Upgrades Fluidigm to Outperform
Mar 22, 2011
Feb 10, 2011
Jan 7, 2011
Caliper Downgraded by Leerink Swann
Nov 23, 2009